Last Updated: 12 June 2020, 2:11PM (NZDT)
The WHO provides helpful information on COVID-19 which includes:
The WHO refers to the use of NHF therapy for pre-oxygenation prior to intubation and for noninvasive respiratory support with close monitoring of clinical deterioration in selected patients with hypoxemic respiratory failure.4
Most of the published data and opinion on the management of COVID-19 comes from clinical experience and restrospective observation. Although reports vary, they include hypoxemic respiratory failure and the use of NHF to reduce the need for tracheal intubation.
A retrospective observational study published in Annals of Intensive Care by Wang et al.1 describes the experience of using NHF therapy in patients with COVID-19.
A recent publication in The Lancet from Phua et al.2 reviewed available evidence and experience to outline recommendations relating to the challenges of managing of COVID-19.
Another recent publication by Sun et al.3 in Annals of Intensive Care retrospectively examined their approach in order to determine factors for reducing COVID-19 related mortality.
The WHO outlines additional precautions that should be taken to protect healthcare workers during aerosol-generating procedures associated with an increased risk of transmission6. These procedures include tracheal intubation, noninvasive ventilation, tracheotomy, cardiopulmonary resuscitation, manual ventilation before intubation and bronchoscopy.
NHF is not specifically named by the WHO as an aerosol-generating procedure associated with an increased risk of transmission.6 However, there has been some uncertainty about the potential creation of aerosols from all forms of noninvasive respiratory support including NHF.
According to the WHO: “Because of uncertainty around the potential for aerosolization, HFO, NIV, including bubble CPAP, should be used with airborne precautions until further evaluation of safety can be completed.”4
Recent publications by Hui et al.7, Leung et al.8 and Hui et al.9 compared the application of NHF to a range of alternative therapies and interfaces and did not find an increased risk of transmission via air dispersion. Collated air dispersion results from two studies conducted by Hui et al.7, 9 are illustrated in the chart below.
Li et al.10 reviewed the existing literature and determined that dispersion via NHF shows a similar risk to standard oxygen masks. For resources in which the principle author of this paper discusses their findings in detail, visit The International Society for Aerosols in Medicine’s COVID-19 webpage.11
Ongoing research continues to investigate the risk of transmission of COVID-19 in the clinical setting.
*Dispersion distance data shown on the chart is combined from two studies conducted by the same authors.
The experiments were conducted in rooms with different configurations. Not all of the interfaces depicted were directly compared.
Dr Pandit talks to us about his first-hand experience in treating patients with COVID-19 in Mumbai. He discusses, in detail, when and how he intiates NHF (HFNC) in patients with Acute Hypoxemic Respiratory Failure (AHRF), as well as the benefits of using NHF as a first mode of respiratory support.
How to operate the AIRVO 2, including guidance on how to adjust key settings such as flow, temperature, and how to add supplemental oxygen (if required).
Flow Matters | Edition 10
Updated: 12 June 2020, 2:11PM (NZDT))
COVID-19 Useful Links Document
Published: 12 June 2020, 2:11PM (NZDT)
AIRVO 2 and COVID-19
Updated: 24 March 2020, 4:27PM (NZDT)
A flow range of 2 to 60 L/min allows for use across the care continuum - from the most acute hospital environment to the home
With Optiflow you can independently titrate flow and FiO2 according to your patient's needs
A premium performance respiratory humidifier designed to be easy to set up and use, minimize condensate and provide advanced protection
The adaptable, reliable and robust humidification system. Use with Evaqua™ 2 circuit technology to minimize condensate.